Does the media prefer MIRM or ATAI?

In the previous week, Mirum Pharmaceuticals had 7 more articles in the media than Atai Beckley. MarketBeat recorded 12 mentions for Mirum Pharmaceuticals and 5 mentions for Atai Beckley. Mirum Pharmaceuticals' average media sentiment score of 0.94 beat Atai Beckley's score of 0.62 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atai Beckley 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ATAI or RYTM?

In the previous week, Atai Beckley had 2 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 5 mentions for Atai Beckley and 3 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 1.14 beat Atai Beckley's score of 0.62 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atai Beckley 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PTCT or ATAI?

In the previous week, PTC Therapeutics had 14 more articles in the media than Atai Beckley. MarketBeat recorded 19 mentions for PTC Therapeutics and 5 mentions for Atai Beckley. Atai Beckley's average media sentiment score of 0.62 beat PTC Therapeutics' score of 0.47 indicating that Atai Beckley is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 8 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Atai Beckley 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, LNTH or ATAI?

Lantheus has higher revenue and earnings than Atai Beckley. Atai Beckley is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.55B 4.42 $233.56M $4.15 25.27 Atai Beckley $4.09M 493.56 -$660.05M -$2.23 N/A

Is LNTH or ATAI more profitable?

Lantheus has a net margin of 18.05% compared to Atai Beckley's net margin of -19,019.44%. Lantheus' return on equity of 29.32% beat Atai Beckley's return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 18.05% 29.32% 15.00% Atai Beckley -19,019.44% -89.79% -63.58%

Does the media favor LNTH or ATAI?

In the previous week, Lantheus had 1 more articles in the media than Atai Beckley. MarketBeat recorded 6 mentions for Lantheus and 5 mentions for Atai Beckley. Lantheus' average media sentiment score of 0.84 beat Atai Beckley's score of 0.62 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Atai Beckley 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SRRK or ATAI more profitable?

Scholar Rock has a net margin of 0.00% compared to Atai Beckley's net margin of -19,019.44%. Atai Beckley's return on equity of -89.79% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -163.52% -96.67% Atai Beckley -19,019.44% -89.79% -63.58%

Does the media prefer SRRK or ATAI?

In the previous week, Atai Beckley had 2 more articles in the media than Scholar Rock. MarketBeat recorded 5 mentions for Atai Beckley and 3 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 1.14 beat Atai Beckley's score of 0.62 indicating that Scholar Rock is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atai Beckley 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Atai Beckley (ATAI) Competitors

$5.44 -0.23 (-4.07%)

As of 12:16 PM Eastern

Compare

ATAI vs. MIRM, RYTM, PTCT, LNTH, and SRRK

Should you buy Atai Beckley stock or one of its competitors? MarketBeat compares Atai Beckley with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Atai Beckley include Mirum Pharmaceuticals (MIRM), Rhythm Pharmaceuticals (RYTM), PTC Therapeutics (PTCT), Lantheus (LNTH), and Scholar Rock (SRRK). These companies are all part of the "pharmaceutical products" industry.

How does Atai Beckley compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Atai Beckley (NASDAQ:ATAI) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

Mirum Pharmaceuticals has higher revenue and earnings than Atai Beckley. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	14.05	-$23.36M	-$13.61	N/A
Atai Beckley	$4.09M	493.56	-$660.05M	-$2.23	N/A

Mirum Pharmaceuticals has a beta of 0.48, suggesting that its share price is 52% less volatile than the broader market. Comparatively, Atai Beckley has a beta of 1.56, suggesting that its share price is 56% more volatile than the broader market.

In the previous week, Mirum Pharmaceuticals had 7 more articles in the media than Atai Beckley. MarketBeat recorded 12 mentions for Mirum Pharmaceuticals and 5 mentions for Atai Beckley. Mirum Pharmaceuticals' average media sentiment score of 0.94 beat Atai Beckley's score of 0.62 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atai Beckley	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals presently has a consensus price target of $143.40, suggesting a potential upside of 19.41%. Atai Beckley has a consensus price target of $15.50, suggesting a potential upside of 182.69%. Given Atai Beckley's stronger consensus rating and higher probable upside, analysts plainly believe Atai Beckley is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Atai Beckley	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	3 Strong Buy rating(s)	3.08

Mirum Pharmaceuticals has a net margin of -140.24% compared to Atai Beckley's net margin of -19,019.44%. Mirum Pharmaceuticals' return on equity of -11.28% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Atai Beckley	-19,019.44%	-89.79%	-63.58%

28.4% of Atai Beckley shares are owned by institutional investors. 8.3% of Mirum Pharmaceuticals shares are owned by insiders. Comparatively, 19.8% of Atai Beckley shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Atai Beckley beats Mirum Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Atai Beckley compare to Rhythm Pharmaceuticals?

Atai Beckley (NASDAQ:ATAI) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

In the previous week, Atai Beckley had 2 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 5 mentions for Atai Beckley and 3 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 1.14 beat Atai Beckley's score of 0.62 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atai Beckley	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Atai Beckley has a beta of 1.56, indicating that its share price is 56% more volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.88, indicating that its share price is 88% more volatile than the broader market.

Rhythm Pharmaceuticals has a net margin of -93.33% compared to Atai Beckley's net margin of -19,019.44%. Atai Beckley's return on equity of -89.79% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-19,019.44%	-89.79%	-63.58%
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

Rhythm Pharmaceuticals has higher revenue and earnings than Atai Beckley. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$4.09M	493.56	-$660.05M	-$2.23	N/A
Rhythm Pharmaceuticals	$189.76M	39.75	-$196.54M	-$3.13	N/A

28.4% of Atai Beckley shares are owned by institutional investors. 19.8% of Atai Beckley shares are owned by company insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Atai Beckley currently has a consensus target price of $15.50, indicating a potential upside of 182.69%. Rhythm Pharmaceuticals has a consensus target price of $138.29, indicating a potential upside of 25.63%. Given Atai Beckley's stronger consensus rating and higher possible upside, equities analysts plainly believe Atai Beckley is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	3 Strong Buy rating(s)	3.08
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76

Summary

Atai Beckley beats Rhythm Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Atai Beckley compare to PTC Therapeutics?

PTC Therapeutics (NASDAQ:PTCT) and Atai Beckley (NASDAQ:ATAI) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

PTC Therapeutics presently has a consensus price target of $91.57, indicating a potential upside of 16.79%. Atai Beckley has a consensus price target of $15.50, indicating a potential upside of 182.69%. Given Atai Beckley's stronger consensus rating and higher possible upside, analysts clearly believe Atai Beckley is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.80
Atai Beckley	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	3 Strong Buy rating(s)	3.08

PTC Therapeutics has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market. Comparatively, Atai Beckley has a beta of 1.56, indicating that its stock price is 56% more volatile than the broader market.

PTC Therapeutics has higher revenue and earnings than Atai Beckley. PTC Therapeutics is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	3.76	$682.64M	-$2.33	N/A
Atai Beckley	$4.09M	493.56	-$660.05M	-$2.23	N/A

28.4% of Atai Beckley shares are owned by institutional investors. 5.5% of PTC Therapeutics shares are owned by insiders. Comparatively, 19.8% of Atai Beckley shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, PTC Therapeutics had 14 more articles in the media than Atai Beckley. MarketBeat recorded 19 mentions for PTC Therapeutics and 5 mentions for Atai Beckley. Atai Beckley's average media sentiment score of 0.62 beat PTC Therapeutics' score of 0.47 indicating that Atai Beckley is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	8 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Atai Beckley	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PTC Therapeutics has a net margin of -22.58% compared to Atai Beckley's net margin of -19,019.44%. Atai Beckley's return on equity of -89.79% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-22.58%	-362.45%	-6.76%
Atai Beckley	-19,019.44%	-89.79%	-63.58%

Summary

Atai Beckley beats PTC Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Atai Beckley compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Atai Beckley (NASDAQ:ATAI) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends.

99.1% of Lantheus shares are held by institutional investors. Comparatively, 28.4% of Atai Beckley shares are held by institutional investors. 1.7% of Lantheus shares are held by company insiders. Comparatively, 19.8% of Atai Beckley shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Lantheus has a net margin of 18.05% compared to Atai Beckley's net margin of -19,019.44%. Lantheus' return on equity of 29.32% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Atai Beckley	-19,019.44%	-89.79%	-63.58%

Lantheus has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market. Comparatively, Atai Beckley has a beta of 1.56, indicating that its stock price is 56% more volatile than the broader market.

Lantheus presently has a consensus target price of $109.00, indicating a potential upside of 3.94%. Atai Beckley has a consensus target price of $15.50, indicating a potential upside of 182.69%. Given Atai Beckley's stronger consensus rating and higher probable upside, analysts plainly believe Atai Beckley is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Atai Beckley	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	3 Strong Buy rating(s)	3.08

Lantheus has higher revenue and earnings than Atai Beckley. Atai Beckley is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.55B	4.42	$233.56M	$4.15	25.27
Atai Beckley	$4.09M	493.56	-$660.05M	-$2.23	N/A

In the previous week, Lantheus had 1 more articles in the media than Atai Beckley. MarketBeat recorded 6 mentions for Lantheus and 5 mentions for Atai Beckley. Lantheus' average media sentiment score of 0.84 beat Atai Beckley's score of 0.62 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Atai Beckley	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lantheus beats Atai Beckley on 10 of the 16 factors compared between the two stocks.

How does Atai Beckley compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Atai Beckley (NASDAQ:ATAI) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 28.4% of Atai Beckley shares are held by institutional investors. 10.3% of Scholar Rock shares are held by company insiders. Comparatively, 19.8% of Atai Beckley shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Scholar Rock has higher earnings, but lower revenue than Atai Beckley. Scholar Rock is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
Atai Beckley	$4.09M	493.56	-$660.05M	-$2.23	N/A

Scholar Rock presently has a consensus target price of $56.00, suggesting a potential upside of 3.68%. Atai Beckley has a consensus target price of $15.50, suggesting a potential upside of 182.69%. Given Atai Beckley's higher probable upside, analysts plainly believe Atai Beckley is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12
Atai Beckley	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	3 Strong Buy rating(s)	3.08

Scholar Rock has a net margin of 0.00% compared to Atai Beckley's net margin of -19,019.44%. Atai Beckley's return on equity of -89.79% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
Atai Beckley	-19,019.44%	-89.79%	-63.58%

Scholar Rock has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market. Comparatively, Atai Beckley has a beta of 1.56, suggesting that its share price is 56% more volatile than the broader market.

In the previous week, Atai Beckley had 2 more articles in the media than Scholar Rock. MarketBeat recorded 5 mentions for Atai Beckley and 3 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 1.14 beat Atai Beckley's score of 0.62 indicating that Scholar Rock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atai Beckley	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Atai Beckley beats Scholar Rock on 9 of the 16 factors compared between the two stocks.

Get Atai Beckley News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATAI vs. The Competition

Export

Metric	Atai Beckley	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.01B	$6.23B	$6.78B	$12.59B
Dividend Yield	N/A	1.42%	2.68%	8.42%
P/E Ratio	-2.45	40.79	26.98	24.43
Price / Sales	493.56	31.01	519.22	91.44
Price / Cash	N/A	19.22	48.59	59.36
Price / Book	7.95	3.74	10.92	6.33
Net Income	-$660.05M	$218.81M	$3.59B	$331.13M
7 Day Performance	6.05%	0.90%	-1.32%	0.39%
1 Month Performance	42.79%	13.51%	2.92%	-0.53%
1 Year Performance	106.91%	37.96%	28.48%	20.45%

Atai Beckley Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATAI Atai Beckley	3.6737 of 5 stars	$5.44 -4.1%	$15.50 +185.0%	+108.5%	$2.00B	$4.09M	N/A	80	Analyst Upgrade Options Volume
MIRM Mirum Pharmaceuticals	2.7156 of 5 stars	$119.04 -2.5%	$143.40 +20.5%	+126.9%	$7.45B	$521.31M	N/A	140
RYTM Rhythm Pharmaceuticals	3.0352 of 5 stars	$107.49 -0.8%	$138.29 +28.6%	+23.3%	$7.43B	$189.76M	N/A	140	Positive News
PTCT PTC Therapeutics	3.327 of 5 stars	$81.33 -4.1%	$91.57 +12.6%	+57.8%	$7.04B	$1.73B	N/A	1,410	Insider Trade
LNTH Lantheus	3.0459 of 5 stars	$105.39 -0.2%	$108.29 +2.7%	+23.2%	$6.88B	$1.54B	25.40	1,193	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATAI) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atai Beckley (ATAI) Competitors

ATAI vs. MIRM, RYTM, PTCT, LNTH, and SRRK

How does Atai Beckley compare to Mirum Pharmaceuticals?

Summary

How does Atai Beckley compare to Rhythm Pharmaceuticals?

Summary

How does Atai Beckley compare to PTC Therapeutics?

Summary

How does Atai Beckley compare to Lantheus?

Summary

How does Atai Beckley compare to Scholar Rock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATAI vs. The Competition

Atai Beckley Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atai Beckley (ATAI) Competitors

ATAI vs. MIRM, RYTM, PTCT, LNTH, and SRRK

How does Atai Beckley compare to Mirum Pharmaceuticals?

Which has preferable earnings & valuation, MIRM or ATAI?

Which has more volatility and risk, MIRM or ATAI?

Does the media prefer MIRM or ATAI?

Do analysts rate MIRM or ATAI?

Is MIRM or ATAI more profitable?

Do insiders & institutionals hold more shares of MIRM or ATAI?

Summary

How does Atai Beckley compare to Rhythm Pharmaceuticals?

Does the media prefer ATAI or RYTM?

Which has more volatility and risk, ATAI or RYTM?

Is ATAI or RYTM more profitable?

Which has stronger earnings & valuation, ATAI or RYTM?

Do institutionals and insiders believe in ATAI or RYTM?

Do analysts recommend ATAI or RYTM?

Summary

How does Atai Beckley compare to PTC Therapeutics?

Do analysts recommend PTCT or ATAI?

Which has more volatility & risk, PTCT or ATAI?

Which has better valuation & earnings, PTCT or ATAI?

Do insiders and institutionals believe in PTCT or ATAI?

Does the media prefer PTCT or ATAI?

Is PTCT or ATAI more profitable?

Summary

How does Atai Beckley compare to Lantheus?

Do insiders & institutionals believe in LNTH or ATAI?

Is LNTH or ATAI more profitable?

Which has more risk & volatility, LNTH or ATAI?

Do analysts prefer LNTH or ATAI?

Which has preferable earnings & valuation, LNTH or ATAI?

Does the media favor LNTH or ATAI?

Summary

How does Atai Beckley compare to Scholar Rock?

Do insiders and institutionals hold more shares of SRRK or ATAI?

Which has stronger earnings and valuation, SRRK or ATAI?

Do analysts recommend SRRK or ATAI?

Is SRRK or ATAI more profitable?

Which has more risk & volatility, SRRK or ATAI?

Does the media prefer SRRK or ATAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATAI vs. The Competition

Atai Beckley Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools